{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-female/prescribing-information/topical-minoxidil-2percent-solution/","result":{"pageContext":{"chapter":{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution","depth":2,"htmlHeader":"<!-- begin field d07aaa5b-1ea2-489a-8294-a25694912027 --><h2>Topical minoxidil 2% solution</h2><!-- end field d07aaa5b-1ea2-489a-8294-a25694912027 -->","summary":"","htmlStringContent":"<!-- begin item e3af931e-01d4-4b6a-acc8-ac5dbd275b1b --><!-- begin field 2e6cac23-29e9-4276-ba0f-315c0bf1878e --><ul><li>Topical minoxidil 2% solution is not available to prescribe on the NHS.</li><li>However, it can be purchased over-the-counter, or can be obtained on a private prescription.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">NHS Business Services Authority, 2016</a>]</p><!-- end field 2e6cac23-29e9-4276-ba0f-315c0bf1878e --><!-- end item e3af931e-01d4-4b6a-acc8-ac5dbd275b1b -->","topic":{"id":"34cafa57-9383-5d80-b924-585fddfaf630","topicId":"ee168cae-489c-42c8-b09e-953c3911c90a","topicName":"Alopecia, androgenetic - female","slug":"alopecia-androgenetic-female","lastRevised":"Last revised in May 2016","chapters":[{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"50eed0df-a1f0-5171-9181-43ae31f74c24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a335b9ba-ae97-56fc-8f3c-67269d2cebee","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"423c1f05-2850-5fc3-9dfe-32260c543c30","slug":"changes","fullItemName":"Changes"},{"id":"98782d6b-86e0-52c6-874d-d38c3a7b8b43","slug":"update","fullItemName":"Update"}]},{"id":"c3b76113-c0a5-51d2-9626-e50262eb0b51","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26174a6e-62fc-5925-bdc7-6dec1e3cc672","slug":"goals","fullItemName":"Goals"},{"id":"268ede25-aeb2-59d0-8650-e83fb2b7237c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0de2e8e-6151-5970-b442-dab292556f28","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"beac34dd-51e9-51be-b40d-b68c2f22bab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7238b814-3ad5-52e6-ad73-5c5e25e26035","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16239c30-d709-5fbe-b215-e9181602c63f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3e8ded1e-bf8c-5ab8-bae3-0a3718045265","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a41bf35-6b01-5146-9673-3480759cf2b2","slug":"definition","fullItemName":"Definition"},{"id":"3f9115db-2801-58d5-8b38-614632cc8518","slug":"causes","fullItemName":"Causes"},{"id":"22dc1f21-64e2-59d3-9248-27696a2ff2f3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d994014c-2572-5645-8d46-23c950e5e12f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2055ae4-a6c4-5ea6-8abb-2ada0bfe997f","slug":"complications","fullItemName":"Complications"},{"id":"f6b263b5-2a9d-5889-b83a-31313b2349ba","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d05f7dc4-15b4-51a7-9040-1f13534d2bcd","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations"},{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","fullItemName":"Management","slug":"management","subChapters":[{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution"}]},{"id":"1f4c5c98-e1a3-5353-af89-7c80d4173e69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a13caaee-1053-53e3-9663-af5cdb6967c3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c996db3c-f9be-5ca7-8fbf-6d8cc2a1dccf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"66cae4ab-b2ad-5800-b305-3061debc9954","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4f39a0f4-1a5f-51fa-ad3f-0bc3472e20ae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebbfb681-3de5-545e-9479-c10e9c16eac3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb1f7555-0114-5914-8728-1ba58437da39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2ef85d5b-cf19-51e6-b768-e1dfbdc625a0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8c565550-033c-593a-8ebc-8b6180675da3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 92ac46e5-83ba-4361-8297-cda0dfd8c00f --><h3>What are the contraindications and cautions for topical minoxidil 2%?</h3><!-- end field 92ac46e5-83ba-4361-8297-cda0dfd8c00f -->","summary":"","htmlStringContent":"<!-- begin item 4a472ce0-b394-44ed-9caa-ce7a80e14954 --><!-- begin field b1e79511-b8a7-4d5f-ad81-ac70889ae656 --><ul><li><strong>Topical minoxidil 2% is contraindicated in women who</strong><strong>:</strong><ul><li>Are not aged 18-65 years. </li><li>Are hypersensitive to minoxidil, or any other ingredients such as ethanol or propylene glycol.</li><li>Have treated or untreated hypertension.</li><li>Have a skin problem on the scalp, such as psoriasis or sunburn.</li><li>Have a shaved scalp.</li><li>Are using other topical medical preparations on the scalp.</li><li>Are pregnant or breastfeeding.<ul><li>There are no adequate and well controlled studies of topical minoxidil in pregnant and lactating women. Studies in animals have shown a risk to the fetus at exposure levels that are very high compared to those intended for human exposure. However, there is potentially a risk of fetal harm in humans [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>].</li><li>Minoxidil is excreted into breast milk in very small amounts. Although topical minoxidil is considered to pose a negligible risk to a breastfeeding infant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">UK Drugs in Lactation Advisory Service, 2015</a>], there is no published evidence on its safe use in breastfeeding, and the manufacturer recommends that it should be avoided in lactating women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>].</li></ul></li></ul></li><li>Topical minoxidil should be used with caution in people with known cardiovascular disease or cardiac arrhythmias. </li><li>Advise women to wash hands thoroughly after applying the solution.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BNF 71, 2016</a>]</p><!-- end field b1e79511-b8a7-4d5f-ad81-ac70889ae656 --><!-- end item 4a472ce0-b394-44ed-9caa-ce7a80e14954 -->","subChapters":[]},{"id":"cd28f107-dd65-5cb5-8414-bee37284271c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a43c81ec-22b9-449e-87a3-f44f2cd462bd --><h3>What are the adverse effects of topical minoxidil 2%?</h3><!-- end field a43c81ec-22b9-449e-87a3-f44f2cd462bd -->","summary":"","htmlStringContent":"<!-- begin item 1e3bd1c0-ba22-4722-b811-ecd0ff60766b --><!-- begin field 44d25dc2-241f-48be-93a6-718f6c8287f6 --><ul><li><strong>Adverse effects of topical minoxidil</strong><strong> 2% may include:</strong><ul><li>Hypertrichosis (unwanted non-scalp hair, including facial hair growth) in women.<ul><li>Facial hypertrichosis has been reported to be a dose-related adverse effect in around 4% of women treated with topical minoxidil [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Dawber and Rundegren, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Thiedke, 2003</a>].</li><li>The woman can be reassured that this hair disappears after 1 year with continued treatment. If application is discontinued, this hair disappears in 1–6 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Levy and Emer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Torres et al, 2015</a>].</li></ul></li><li>Local redness, itching, and flaking. Skin reactions are largely due to the presence of the propylene glycol vehicle.<ul><li>Treatment should be discontinued if there is persistent redness or irritation of the scalp. </li></ul></li><li>Increased hair shedding generally occurring 2–6 weeks after initiating treatment. It is temporary and subsides within a few weeks.<ul><li>Treatment should be discontinued if shedding persists for more than 2 weeks.</li></ul></li></ul></li><li>There is no clear increased risk of cardiovascular complications with the use of topical minoxidil (because systemic absorption through normal skin is very low). However, cases of hypotension have been reported rarely, and treatment should be discontinued if the woman experiences chest pain, syncope, or dizziness. </li><li>The manufacturer also recommends discontinuing treatment if the person experiences sudden unexplained weight gain, or swollen hands or feet.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BNF 71, 2016</a>]</p><!-- end field 44d25dc2-241f-48be-93a6-718f6c8287f6 --><!-- end item 1e3bd1c0-ba22-4722-b811-ecd0ff60766b -->","subChapters":[]},{"id":"dfe6782a-6800-5115-85b3-8219e6fd071a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6b2d017b-8e0e-4b91-9043-e4d6ed781a4a --><h3>What are the drug interactions of topical minoxidil 2%?</h3><!-- end field 6b2d017b-8e0e-4b91-9043-e4d6ed781a4a -->","summary":"","htmlStringContent":"<!-- begin item 765a1c01-7420-4368-952c-e562f0b0490e --><!-- begin field 5d377f4c-3409-4ac9-a9fc-91f3adda48c9 --><ul><li>There is a theoretical possibility that absorbed minoxidil can potentiate orthostatic hypotension caused by other antihypertensive drugs.</li><li>Application of other topical drugs, such as topical corticosteroids, tretinoin, or dithranol, may increase absorption of minoxidil.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>]</p><!-- end field 5d377f4c-3409-4ac9-a9fc-91f3adda48c9 --><!-- end item 765a1c01-7420-4368-952c-e562f0b0490e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}